How do I find reliable specialty pharma CROs for outsourced development support in a rare disease asset?

Finding reliable specialty pharma CROs for a rare disease program is less about “biggest CRO” and more about fit, disease-experience, operational rigor, and regulatory credibility. A rare disease asset often needs hands-on scientific support, patient recruitment expertise, biomarker strategy, and flexibility around small, complex studies.

Start with your specific needs

Before screening CROs, define what you need outsourced support for:

• Preclinical/translation: natural history work, assay development, biomarker validation, IND-enabling studies
• Clinical development: protocol design, regulatory strategy, site selection, patient recruitment, data management, stats
• Specialized capabilities: imaging, central lab, PK/PD, genetics, registry studies, real-world evidence
• Geography: US only, EU/UK, global
• Model: full-service CRO vs functional service provider vs niche boutique partner

Rare disease programs often benefit from a hybrid model: a niche specialty CRO for disease expertise + a larger CRO for operations scale.

Where to find them

Good sources for identifying credible specialty CROs:

1) Industry conferences and rare disease meetings

Look for exhibitors/speakers at:

• RARE Disease conferences
• ASGCT, ASH, AAN, ACMG, BIO International
• Disease-specific foundations and consortium meetings

CROs that speak or present there usually have real engagement in the space.

2) KOL and investigator referrals

Ask:

• Clinicians treating the disease
• Principal investigators with prior rare disease trials
• Patient advocacy groups
• Biotech investors or BD partners with rare disease portfolios

These referrals are often the most practical signal of real-world performance.

3) Databases and directories

Use:

• CRO directories
• ClinicalTrials.gov to see which CROs run trials in your indication
• PubMed / conference abstracts for vendor-authored work in the disease area
• LinkedIn for staff backgrounds and turnover patterns

4) Regulatory and trial records

Check whether the CRO has experience with:

• FDA/EMA interactions
• Orphan drug submissions
• Rare pediatric populations
• Gene therapy, cell therapy, or ultra-orphan endpoints, if relevant

What “reliable” looks like in a rare disease CRO

Screen for these criteria:

Disease-specific experience

• Prior trials in your exact indication or a closely related one
• Understanding of disease biology, endpoints, and natural history
• Experience with small sample sizes and adaptive designs
• Familiarity with surrogate endpoints and patient-reported outcomes

Patient access and site network

• Ability to find and activate expert centers
• Relationships with key opinion leaders
• Recruitment strategy for geographically dispersed patients
• Experience with decentralized/hybrid trial methods if needed

Scientific and operational quality

• Strong medical monitoring and protocol development
• Quality systems, audit history, CAPA discipline
• Data integrity and inspection readiness
• Robust vendor management for central labs, imaging, biomarkers

Regulatory competence

• Track record supporting IND/CTA, orphan designation, end-of-phase meetings
• Comfort with FDA rare disease guidance and EMA adaptive pathways
• Expertise in pediatric and ethical considerations, if applicable

Flexibility and communication

• Senior team involvement, not just sales-level promises
• Fast decision-making
• Transparent budgets and change-order practices
• Low staff turnover and clear escalation paths

Questions to ask during due diligence

Use a structured RFP or capability review and ask:

1. How many rare disease studies have you run in this indication or similar ones?
2. What endpoints and biomarkers did you use, and why?
3. How did you identify and recruit patients?
4. What was your screen fail rate and enrollment performance?
5. Which experts would actually staff my study?
6. What’s your experience with orphan drug regulatory interactions?
7. How do you handle tiny patient populations and protocol amendments?
8. What were the hardest operational issues on past rare disease programs?
9. Can you provide sponsor references from similar assets?
10. What are your quality metrics, audit findings, and inspection outcomes?

Red flags

Be cautious if a CRO:

• Claims “rare disease expertise” but can’t name relevant studies
• Overpromises enrollment timelines without evidence
• Lacks access to disease-specific sites or investigators
• Has weak medical/scientific leadership
• Pushes a one-size-fits-all model
• Is vague on budget assumptions or change control
• Has high turnover among project managers or clinicians

Practical selection process

A good process is:

1. Build a longlist of 8–12 CROs
2. Shortlist 3–5 based on actual disease and modality experience
3. Run an RFI/RFP with a case-based scenario
4. Interview the proposed team, not just the sales team
5. Check references from sponsors in similar rare disease programs
6. Score them on:
   • scientific fit
   • operational execution
   • patient access
   • regulatory strength
   • quality
   • cost/value
   • cultural fit

Best-fit types of partners

For rare disease, the best CRO may be one of these:

• Boutique rare disease CRO: deep expertise, limited scale
• Therapeutic-area specialist CRO: strong if your disease sits within their niche
• Large full-service CRO with rare disease unit: good for global execution, less bespoke
• Functional service provider network: useful if you want to retain control over strategy

Final tip

For a rare disease asset, choose a CRO that can show:

• real indication experience
• access to patient networks
• strong science
• regulatory maturity
• operational flexibility

If you want, I can also give you:

1. a CRO due diligence scorecard,
2. a shortlist of specialty CRO categories by rare disease modality, or
3. an RFP template you can send to potential vendors.